Agents for attention-deficit hyperactivity disorder – an update

Bibliography

• Diagnostic and Statistical Manual of Mental Disorders (DSM-II) (4th Ed.)Task Force on DSM-IV. Am. Psych. Assoc., Washington DC, USA (1994).
   Google Scholar
• VOLKOW ND, SWANSON JM: Variables That affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry (2003) 160(11):1909–1918.
   PubMed Web of Science ®Google Scholar
• Startling new study released: girls with ADHD are often overlooked. PRNewswire (4 September 2002).
   Google Scholar
• ADHD Diagnosis missed in 85% of adult sufferers. PRNewswire (3 June 2003).
   Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER TJ: Attention deficit/ hyperactivity disorder across the lifespan. Ann. Rev. Med. (2003) 53:113–131.
   Web of Science ®Google Scholar
• Adult alcoholism and attention-deficit hyperactivity disorder are connected. EurekAlert (14 October 2003).
   Google Scholar
• SULLIVAN MA, RUDNIK-LEVIN F: Attention deficit/hyperactivity disorder and substance abuse: diagnostic and therapeutic considerations. Ann. NY Acad. Sci. (2001) 931(Adult Attention Deficit Disorder):251–270.
   Google Scholar
• FARAONE SV, WILENS T: Does stimulant treatment lead to substance use disorders? Clin. Psychiatry (2003) 64\(Supp1.11):9–13.
   Google Scholar
• LIE N: Follow-ups of children with attention deficit hyperactivity disorder (ADHD). Review of literature. Acta Psychiatr. Scand. (1992) 368(Suppl.):1–40.
   Google Scholar
• MCKAY KE, HALPERIN JM: ADHD, aggression and antisocial behavior across the lifespan: interactions with neurochemical and cognitive function. Ann. NY Acad. Sci. (2001) 931:84–96.
   PubMed Web of Science ®Google Scholar
• YOUNG S, TOONE B, TYSON C: Comorbidity and psychosocial profile of adults with attention deficit hyperactivity disorder. Pers. Individ. Dif (2003) 35:743–755.
   Web of Science ®Google Scholar
• BIEDERMAN J: Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Clin . Psychiatry (2003) 64\(Supp1.11):3–8.
   Google Scholar
• SWANSON J, DEUTSCH C, CANTWELL D et al: Genes and attention-deficit hyperactivity disorder. Clin. Neurosci. Res. (2001) 1(3):207–216.
   Google Scholar
• THAPAR A: Attention deficit hyperactivity disorder: unraveling the molecular genetics. MM. Psychiatry(1998) 3(5):370–372.
   Google Scholar
• DURSTON S: A review of the biological bases of ADHD: what have we learned from imaging studies? Merit. Retard. Develop. Disabilities Res. Rev (2003) 9:184–195.
   PubMedGoogle Scholar
• SEEMAN P, MADRAS BK: Antihyperactivity medication: methylphenidate and amphetamine. Ma Psychiatry (1998) 3(5):386–396.
   Google Scholar
• EFRON D, JARMAN F, BARKER M: Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics (1997) 100(4):662–666.
   PubMed Web of Science ®Google Scholar
• IBRAHIM ESR: Rates of adherence to pharmacological treatment among children and adolescents with attention deficit hyperactivity disorder. Hum. Psychopharmacol Clin. Exp. (2000) 17:225–231.
   Web of Science ®Google Scholar
• WENDER PH, WOLF LE, WASSERSTEIN J: Adults with ADHD. An Overview. Ann. NY Acad. Sci. (2001) 931:1–16.
   PubMed Web of Science ®Google Scholar
• EDWARDS LA: A comparison of the newer treatment options for ADHD. Formulary (2003) 38:38–52.
   Web of Science ®Google Scholar
• Attention deficit drugs may have long-term effects. Reuters Health Professional Medical News (9 December 2003).
   Google Scholar
• Ritalin shows unexpected effect in back of brain, study finds. Wall Street J. (01/08/ 2002).
   Google Scholar
• CASTELLANOS XF, LEE PP, SHARP W et al.: Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA (2002) 288:1740–1748.
   PubMed Web of Science ®Google Scholar
• SCHWEITZER JB, HOLCOMB HH: Drugs under investigation for attention-deficit hyperactivity disorder. Can: Opin. Invest. Drugs (2002) 3(8):1207–1211.
   PubMedGoogle Scholar
• •Excellent review of promising new drugs in the pipeline for ADHD treatment.
   Google Scholar
• Atomoxetine hydrochloride in children and adults with ADHD. Prous Daily Essentials (6 October 2003).
   Google Scholar
• New studies on atomoxetine presented at the APA meeting. Prous Daily Essentials (30 June 2003).
   Google Scholar
• WERNICKE JF, KRATOCHVIL CJ: Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. I Clin. Psychiatry (2002) 63\(Supp1.12):50–55.
   Google Scholar
• Eli Lilly & Co.: Strattera prescriptions double in three-month period. Business Wire (16 October 2003).
   Google Scholar
• MAIDMENT ID: The use of antidepressants to treat attention deficit hyperactivity disorder in adults. Psychopharmacol (2003) 17(3):332–336.
   Web of Science ®Google Scholar
• SPENCER TJ, BIEDERMAN J, WILENS TE, FARAONE SV: Novel treatments for attention-deficit/ hyperactivity disorder in children. I. Clin. Psychiatry (2002) 63 (Suppl. 12):16–22.
   Google Scholar
• HOWARD HR: Therapeutic agents for attention deficit disorders. Expert Opin. Ther. Patents (2000) 10:1549–1559.
   Web of Science ®Google Scholar
• GAINETDINOV RR, WETSEL WC, JONES SR, LEVIN ED, JABER M, CARON MG: Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science (1999) 283(5400):397–401.
   PubMed Web of Science ®Google Scholar
• OHNO M: The dopaminergic system in attention deficit/hyperactivity disorder. Congenital Anomalies (2003) 43(2):114–122.
   PubMedGoogle Scholar
• KIRLEY A, HAWI Z, DALY G et al.: Dopaminergic system genes in ADHD. Toward a biological hypothesis. Neuropsychopharmacology (2002) 27(4):607–619.
   PubMed Web of Science ®Google Scholar
• ROWE DC, STEVER C, CHASE D, SHERMAN S, ABRAMOWITZ A, WALDMAN ID: Two dopamine genes related to reports of childhood retrospective inattention and conduct disorder symptoms. Psychiatry (2001) 6:429–433.
   Google Scholar
• MADRAS BK, MILLER GM, FISCHMAN AJ: The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav. Brain Res. (2002) 130(1,2):57–63.
   Google Scholar
• ROMAN T, SZOBOT C, MARTINS S, BIEDERMAN J, ROHDE LA, HUTZ MH: Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics (2002) 12:497–499.
   PubMedGoogle Scholar
• RETZ W, ROSLER M, SUPPRIAN T, RETZ-JUNGINGER P, THOME J: Dopamine D3 receptor gene polymorphism and violent behavior: relation to impulsiveness and ADHD-related psychopathology. J. Neural Transm. (2003) 110:561–572.
   PubMed Web of Science ®Google Scholar
• TODD RD, O'MALLEY KL: The dopamine receptor DRD4 gene: are duplications distracting? Trends Pharmacol Sci. (2001) 22(2):55–56.
   Google Scholar
• RUBINSTEIN M, CEPEDA C, HURST RS et al.: Dopamine D4 receptor-deficient mice display cortical hyperexcitability. Neurosci. (2001) 21(11):3756–3763.
   Web of Science ®Google Scholar
• MENESES A: 5-HT system and cognition. Neurosci. Behav. Rev (1999) 23:1111–1125.
   PubMed Web of Science ®Google Scholar
• ••Very detailed review of the recent status ofserotonin research.
   Google Scholar
• KOSKINEN T, RUOTSALAINEN S, SIRVIO J: The 5-HT2 receptor activation enhances impulsive responding without increasing motor activity in rats. Pharmacol Biochem. Behav. (2000) 66(4):729–738.
   PubMed Web of Science ®Google Scholar
• KOHEN R, METCALF MA, KHAN N et al.: Cloning, characterization and chromosomal localization of a human 5-HT6serotonin receptor. J. Neurochem. (1996) 66(1):47–56.
   PubMed Web of Science ®Google Scholar
• BROMIDGE SM, BROWN AM, CLARKE SE et al: 5-Chloro N (4 methoxy-3-piperazin-1-ylpheny1)-3-methy1-2-benzothiophenesulfonamide (SB-271046): a potent, selective and orally bioavailable 5-HT6 receptor antagonist. J. Med. Chem. (1999) 42(2):202–205.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, SPENCER T: Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry (1999) 46(9):1234–1242.
   PubMed Web of Science ®Google Scholar
• CANT WELL DP: ADHD through the life span: the role of bupropion in treatment. Clin. Psychiatry(1998) 59\(Supp1.4):92–94.
   Google Scholar
• DAVISS WB, PAN RJ, PEREL JM: Bupropion for attention deficit hyperactivity and comorbid disorders. Exp. Rev Neurothempeutics (2003) 3(1):9–18.
   PubMedGoogle Scholar
• WILENS TE, PRINCE JB, SPENCER T et al.: An open trial of bupropion for the treatment of adults with attention-deficit/ hyperactivity disorder and bipolar disorder. Biol. Psychiatry (2003) 54:9–16.
   PubMed Web of Science ®Google Scholar
• ROSENBERG DR: Adrenergic agents in child and adolescents psychiatry. Med. Psychiatry (2002) 18:543–595.
   Google Scholar
• LEURS R, WATANABE T, TIMMERMAN H: Histamine receptors are finally 'coming out'. Trends Pharmacol Sci. (2001) 22(7):337–339.
   Google Scholar
• CHAZOT PL, HANN V: H3 histamine receptor isoforms: new therapeutic targets in the CNS? CLIFF. Opin. Invest. Drugs (2001) 2(10):1428–1431.
   PubMedGoogle Scholar
• STARK H: Recent advances in histamine H3/H4 receptor ligands. Expert Opin. Ther. Patents (2003) 13(6):851–865.
   Web of Science ®Google Scholar
• •Discussion of the newest member of the histamine receptor family.
   Google Scholar
• PHILLIPS JG, ALT SM, YATES SL, TEDFORD CE: Recent advances in histamine H3 receptor agents. Ann. Rep. Med. Chem. (1998) 33:31–40.
   Google Scholar
• ABT-239, a nonimidazole H3 receptor antagonist with cognition-enhancing effects. Prous Daily Essentials (12 November 2003).
   Google Scholar
• FAGHIH R, BENNANI YL, BLACK LA et al.: Histamine H3 receptor antagonists: from high throughput screening (HTS) to drug-like molecules. Abstracts of the American Chemical Society Division of Medicinal Chemistry 226th National Meeting. New York, NY (7–11 September 2003) Medi 54.
   Google Scholar
• UENO K-I, IOGASHI H, MATSUMOTO M, OHASHI S, SAITO H, YOSHIOKA M: a4132 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior. I. Stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder. .1. Pharm. Exp. Ther. (2002) 302:95–100.
   Google Scholar
• MORAN PM, KANE JM, MOSER PC: Enhancement of working memory performance in the rat by MDL 26,479, a novel compound with activity at the GABA-A receptor complex. Brazil Res. (1992) 569(1):156–158.
   Google Scholar
• COURVOISIE H, HOOPER SR, FINE C, KWOCK L, CASTILLO M: Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings. Neuropsychiatry Chu. Neurosci. (2004) 16(1):63–69.
   PubMed Web of Science ®Google Scholar
• CARLSSON ML: On the role of corticalglutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr. Scand. (2000) 102 (6):401–413.
   PubMed Web of Science ®Google Scholar
• RUGINO TA, SAMSOCK TC: Modafinil in children with attention-deficit hyperactivity disorder. Pediam Neurol (2003) 29(2):136–142.
   PubMed Web of Science ®Google Scholar
• Modafinil may have a role in the treatment of ADHD in children. Reuters Health (29 October 2002).
   Google Scholar
• SCHWEITZER JB, HOLCOMB HH: Drugs under investigation for attention-deficit hyperactivity disorder. Curt: Opin. Invest. Drugs. (2002) 3(8):1207–1211.
   PubMedGoogle Scholar
• PONCE G, HOENICKA J, RUBIO G et al.: Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol. Psychiatry (2003) 8:466–467.
   PubMed Web of Science ®Google Scholar
• AKHONDZADEH S, TAVAKOLIAN R, DAVARI-ASHTIANI R, ARABGOL F, AMINI H: Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double-blind and randomized trial. Frog. Neuro-Psychopharmacol Biol. Psychiatry (2003) 27(5):841–845.
   PubMed Web of Science ®Google Scholar
• BOIX F, QIAO S, KOLPUS T, SAGVOLDEN T: Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of attention deficit hyperactivity disorder. Behav. Brain Res. (1998) 94(1):153–162.
   PubMed Web of Science ®Google Scholar